1132610-47-9 Usage
Uses
Used in Pharmaceutical Research:
Ethanone, 1-(5-fluoro-6-Methyl-2-pyridinyl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-ylis utilized as a potential drug candidate for the development of new therapeutic agents. Its unique chemical structure offers opportunities for the exploration of novel mechanisms of action that could be beneficial in treating various diseases.
Used in Oncology:
In the field of oncology, Ethanone, 1-(5-fluoro-6-Methyl-2-pyridinyl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl- is being studied for its potential applications in the treatment of certain types of cancer. The specific cancers it may target and its mechanism of action in these contexts are still under investigation, but its presence in pharmaceutical research indicates a focus on identifying its role in cancer therapy.
Used in Medicinal Chemistry:
Ethanone, 1-(5-fluoro-6-Methyl-2-pyridinyl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-ylis also used in medicinal chemistry for further exploration of its properties and potential applications. Researchers are interested in understanding how its structure can be modified or leveraged to create more effective and targeted treatments for various medical conditions, including but not limited to cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1132610-47-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,2,6,1 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1132610-47:
(9*1)+(8*1)+(7*3)+(6*2)+(5*6)+(4*1)+(3*0)+(2*4)+(1*7)=99
99 % 10 = 9
So 1132610-47-9 is a valid CAS Registry Number.
InChI:InChI=1S/C14H11FN4O/c1-9-11(15)3-4-12(18-9)13(20)6-10-2-5-14-16-8-17-19(14)7-10/h2-5,7-8H,6H2,1H3
1132610-47-9Relevant academic research and scientific papers
Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type i receptor kinase
Krishnaiah, Maddeboina,Jin, Cheng Hua,Sheen, Yhun Yhong,Kim, Dae-Kee
supporting information, p. 5228 - 5231 (2015/11/09)
To further optimize a clinical candidate 5 (EW-7197), a series of 5-(3-, 4-, or 5-fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles 19a-l have been synthesized and evaluated for their TGF-β type I receptor kinase (ALK5) and p38α MAP kinase inhibitory activity in an enzyme assay. The 5-(5-fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles 19h-l displayed the similar level of potency to that of 5 against both ALK5 (IC50 = 7.68-13.70 nM) and p38α MAP kinase (IC50 = 1240-3370 nM). Among them, 19j inhibited ALK5 with IC50 value of 7.68 nM in a kinase assay and displayed 82% inhibition at 100 nM in a luciferase reporter assay.
2-Aminoimidazoles inhibitors of TGF-β receptor 1
Bonafoux, Dominique,Chuaqui, Claudio,Boriack-Sjodin, P. Ann,Fitch, Chris,Hankins, Gretchen,Josiah, Serene,Black, Cheryl,Hetu, Gregg,Ling, Leona,Lee, Wen-Cherng
scheme or table, p. 912 - 916 (2009/10/15)
The 4-(5-fluoro-6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-ylamine 3 is a potent and selective inhibitor of TGF-βR1. Substitution of the amino group of 3 typically led to a slight decrease in the affinity for the receptor and in TGF-β-inducted
